** Medadvisor MDR.AX slides 12.7% to A$0.096, lowest since March 21
** Medication solutions co expects FY25 loss before interest, taxes, depreciation and amortization to be in the A$2.6 mln ($1.6 mln)-A$5.5 mln range
** Co reported FY24 EBITDA at A$7 mln
** MDR expects FY25 revenue between A$93 mln and A$99 mln, lower than year-ago A$122 mln
** Stock on track for weakest session since March 21
** MDR sheds 51.1% YTD
($1 = A$1.6023)
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。